Non-transplantable recurrence after percutaneous thermal ablation of ≤3-cm HCC: Predictors and implications for treatment allocation.

Autor: Gozzo C; Department of RadiologySt-Eloi University HospitalMontpellierFrance.; Radiodiagnostic and Radiotherapy Unit, Department of Medical and Surgical Sciences and Advanced Technologies 'GF Ingrassia'University of CataniaCataniaItaly., Hermida M; Department of RadiologySt-Eloi University HospitalMontpellierFrance., Herrero A; Department of Liver SurgerySt-Eloi University HospitalMontpellierFrance., Panaro F; Division of HBP Surgery & Transplantation, Department of SurgeryMontpellier University HospitalMontpellierFrance., Cassinotto C; Department of RadiologySt-Eloi University HospitalMontpellierFrance., Mohamad AM; Department of RadiologySt-Eloi University HospitalMontpellierFrance., Assenat E; Department of OncologySt-Eloi University HospitalMontpellierFrance.; Department of HepatologySt-Eloi University HospitalMontpellierFrance., Guillot C; Department of RadiologySt-Eloi University HospitalMontpellierFrance., Allimant C; Department of RadiologySt-Eloi University HospitalMontpellierFrance., Schembri V; Department of RadiologySt-Eloi University HospitalMontpellierFrance., Basile A; Radiodiagnostic and Radiotherapy Unit, Department of Medical and Surgical Sciences and Advanced Technologies 'GF Ingrassia'University of CataniaCataniaItaly., Dharancy S; Department of HepatologyLille University HospitalLilleFrance., Ursic-Bedoya J; Department of Liver SurgerySt-Eloi University HospitalMontpellierFrance., Guiu B; Department of RadiologySt-Eloi University HospitalMontpellierFrance.
Jazyk: angličtina
Zdroj: Hepatology communications [Hepatol Commun] 2022 Oct; Vol. 6 (10), pp. 2975-2987. Date of Electronic Publication: 2022 Aug 06.
DOI: 10.1002/hep4.2063
Abstrakt: Percutaneous thermal ablation (PTA), resection, and liver transplantation are the standard curative options for hepatocellular carcinoma (HCC). Liver transplantation yields the best long-term outcomes but is limited by graft shortage. Thus, patients with ≤3-cm HCC are primarily treated by PTA even though recurrence is frequent and may occur outside transplant criteria. Data on non-transplantable recurrence (NTR) following PTA are lacking, however. We therefore investigated the incidence and predictors of NTR among 213 potentially transplantable patients (cirrhosis, 93%; Child-Pugh A, 98.6%; alcohol-related disease, 62%) with ≤3-cm HCC(s) treated by PTA, to stratify them according to their NTR risk and to improve treatment allocation. During follow-up (median: 41.2 months), NTR occurred in 18.3% (alpha-fetoprotein [AFP] model) and 23% (Milan) patients. NTR prediction with competing-risk analysis and internal validation revealed AFP > 100 ng/ml (subdistribution hazard ratio: 7.28; p < 0.001) and prior HCC (subdistribution hazard ratio: 3.77; p = 0.002) as independent predictors (Harrell's C: 0.76). Based on this model using the AFP score (equally predictive within Milan criteria), patients were stratified into three NTR risk categories: HCC-naïve with AFP < 100 ng/ml (low risk, n = 108 of 213), non-HCC naïve with AFP < 100 ng/ml (intermediate risk, n = 92 of 213), AFP ≥ 100 ng/ml (high risk, n = 13 of 213), among whom 9.3% (3.7% [Milan]), 22.8% (25% [Milan]), and 61.5% (38/5% [Milan]) presented NTR (p < 0.001). Median recurrence-free survival was 4.6, 14.5, and 43.4 months, respectively, in high-risk, intermediate-risk, and low-risk categories (p < 0.001). Median overall survival, which was 19.1 months in high-risk patients, was not reached otherwise (p < 0.001). Conclusion: Overall, PTA of ≤3-cm HCC incurs a low NTR risk. Simple and noninvasive predictors (HCC naivety, AFP) accurately stratified patients' risk of NTR, and should help to improve treatment allocation. Patients with AFP ≥ 100 ng/ml have a high risk of NTR, poor recurrence-free survival, and overall survival. Further studies evaluating preemptive transplantation or adjuvant/neoadjuvant strategies are highly needed in this small patient subset.
(© 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.)
Databáze: MEDLINE
Externí odkaz: